Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Iloprost for Raynaud's Phenomenon in Systemic Sclerosis
NCT03867097Phase 2Completed
- Sponsor
- CiVi Biopharma
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of iloprost in Raynaud phenomenon, sponsored by CiVi Biopharma. Started Mar 2019; status: completed.
02
Drugs
iloprost
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT03867097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867097.